As part of its growth strategy, Arcturus Therapeutics has partnered with The Chase Group to build and expand their vaccines development team. Founded in 2013 and based in San Diego, California, Arcturus is a clinical-stage mRNA medicines and vaccines company with a diverse pipeline of several self-replicating mRNA programs. Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics. The company’s technologies are covered by its extensive patent portfolio (192 patents and patent applications, issued in the U.S., Europe, Japan, China, and other countries). The Chase Group values this partnership with Arcturus and will draw upon a vast network and 25+ years of executive search experience to secure influential leaders who will grow with Arcturus and help them bring life-saving medicines to the world.